|Bid||10.50 x 4000|
|Ask||0.00 x 1800|
|Day's range||10.98 - 11.58|
|52-week range||4.52 - 24.75|
|Beta (5Y monthly)||2.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Ladies and gentlemen, thank you for standing by, and welcome to the Atara Biotherapeutics First Quarter 2020 Financial Results Conference Call. Thank you, Eric, and thanks to all of you for joining us this afternoon.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...